BioPharmSignal logoBioPharmSignal

Biotech News

Innate Pharma reports full year 2025 financial results and business update

Innate Pharma (IPHA)Innate PharmaEarnings

Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille pour l’année 2025

jeu, 03/26/2026 - 07:00

Press Release in English 485.82 Ko Communiqué de presse en français 549.37 Ko Présentation des résultats annuels 2025 1.3 Mo

mathilde

mer, 03/25/2026 - 23:05

Related news

IPHAInnate Pharma2026-07-20 14:53 EST

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

KURAKura Oncology2026-08-12 20:02 EST

Kura Oncology Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

IDYAIDEAYA Biosciences2026-08-04 10:00 EST

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

View all latest news

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

IPHAInnate Pharma2026-08-13 07:14 EST

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

IPHAInnate Pharma2026-08-10 14:02 EST

Innate Pharma Announces Proposed Offering of Ordinary Shares

IPHAInnate Pharma2026-08-09 21:32 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close
2.26 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States